STRATEC increases distribution to shareholders by 50%

The Annual General Meeting of STRATEC Biomedical Systems AG held on Friday passed all of the agenda items requiring shareholders' approval in each case with a considerable majority.

STRATEC will be distributing Euro 0.30 per share to its shareholders for the 2005 financial year (previous year: dividend of Euro 0.15, plus bonus of Euro 0.05). This represents a 50% increase in the distribution per share compared with the previous year.

The Annual General Meeting further approved the issue of bonus shares. As soon as the corresponding resolution has become effective upon being entered in the Commercial Register, each shareholder will receive an additional two new shares (bonus shares) for each existing share. This means that the volumes of STRATEC shares held in shareholders' security accounts will automatically treble. No contribution will be required from shareholders in this respect. The issue of bonus shares is intended to make the share more attractive for investors and to facilitate trading with the share. The execution of this measure will increase STRATEC's share capital from its current level of Euro 3,708,239.00 to Euro 11,124,717.00.

Moreover, STRATEC's shareholders also adopted a resolution authorizing the company's Board of Management to buy back treasury stock and a resolution allowing the granting of stock options and the creation of new conditional capital to service stock option rights. In addition, the shareholders approved the restructuring of supervisory board remuneration, the creation of new authorized capital and a resolution authorizing the Board of Management to issue convertible and warrant bonds. Furthermore, the shareholders authorized the Board of Management to refrain from publishing the remuneration of the Board of Management and the Supervisory Board on an individual basis. Finally, the shareholders approved various amendments to the company's articles of association, particularly with regard to the entry into force of the Act on Corporate Integrity and Modernization of the Right of Contestation (UMAG).

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges.

The STRATEC Group comprises the listed holding company "STRATEC Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen", "Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: [email protected]